Details for Patent: 7,427,600

Title:	Active agent delivery systems and methods for protecting and administering active agents
Abstract:	The present invention relates to active agent delivery systems and more specifically to compositions that comprise amino acids, as single amino acids or peptides, covalently attached to active agents and methods for administering conjugated active agent compositions.
Inventor(s):	Mickle; Travis (Charlottesville, VA), Krishnan; Suma (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Lauderback; Christopher (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Kirk; Randal (Radford, VA)
Assignee:	Shire LLC (Florence, KY)
Filing Date:	Aug 23, 2004
Application Number:	10/923,088
Claims:	1. A method of treating inflammatory bowel disease comprising administering to a patient in need thereof an effective amount of a compound consisting of mesalamine covalently attached to a single amino acid selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof. 2. A compound consisting of mesalamine covalently attached to a single amino acid wherein said single amino acid is selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof. 3. The compound of claim 2, wherein the amino acid is Valine. 4. A pharmaceutical composition comprising: a compound consisting of mesalamine covalently attached to a single amino acid selected from Valine, Alanine, Asparagine, Isoleucine, Proline, Lysine, Cysteine, Glutamine, Histidine, Methionine, Phenylalanine, Serine, Threonine, Tryptophan and Tyrosine or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. 5. The pharmaceutical composition of claim 4, wherein said composition is an oral dosage form. 6. The pharmaceutical composition of claim 4, wherein the compound is mesalamine covalently attached to Valine. 7. The method of claim 1, wherein the compound is mesalamine covalently attached to Valine.